- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Diagnostic and Prognostic Biomarkers
During this opening segment of a one-on-one interview series, Peter Salgo, MD, discusses emerging diagnostic and prognostic biomarkers in prostate cancer with Ira M. Klein, MD, MBA, FACP, national medical director, clinical thought leadership, office of the chief medical officer at Aetna.
When patients with high PSA results undergo a biopsy, providers take into account several factors when deciding on treatment, including the patient’s Gleason score and tumor morphology, as well as the patient’s age and life expectancy, explains Dr Klein. He stresses the importance of emerging biomarkers, and notes that they may help providers determine how best to treat their patients. Unfortunately, there are currently no biomarkers with proven value in metastatic disease, comments Dr Klein.
Dr Klein is optimistic that ongoing trials will help establish the role of additional biomarkers that can help providers track disease progression and personalize treatment.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
